Skip to content

Search

New life breathed into ground-breaking Aboriginal child health survey

In 1998, The Kids Research Institute Australia embarked on one of the most ambitious population health projects in Western Australian history.

Partnership expands Aboriginal kids’ lung health program across Western Australia

A program aimed at raising awareness of the dangers of a chronic wet cough in Aboriginal children has been extended to 14 remote and regional towns in Western Australia - thanks to a partnership between The Kids Research Institute Australia and Cystic Fibrosis WA.

Researchers call for rethink on infant screentime

A The Kids Research Institute Australia study has found the average six-month-old Australian baby has more than one hour of screen time each day.

Healing airways so kids with asthma can breathe better

An exciting study is investigating whether a new therapeutic treatment for asthma will protect young sufferers from ongoing lung damage and improve their long-term health outcomes.

Psychological Flow Scale (PFS): Development and Preliminary Validation of a New Flow Instrument that Measures the Core Experience of Flow to Reflect Recent Conceptual Advancements

In this study, we sought to develop—and provide preliminary validity evidence for scores derived from—a new Psychological Flow Scale (PFS). We propose a parsimonious model of three core dimensions of flow, reflecting the findings from a recent scoping review that synthesised flow research across scientific disciplines.

Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage study

The impact of pneumococcal conjugate vaccines (PCVs) on pneumonia in children is well-documented but data on 23-valent pneumococcal polysaccharide vaccine (PPV23) are lacking. Between 2001 and 2011, Indigenous children in Western Australia (WA) were recommended to receive PPV23 at 18-24 months of age following 3 doses of 7-valent PCV. We evaluated the incremental effectiveness of PPV23 against pneumonia hospitalisation.

A review of pediatric fasting guidelines and strategies to help children manage preoperative fasting

Fasting for surgery is a routine step in the preoperative preparation for surgery. There have however been increasing concerns with regard to the high incidence of prolonged fasting in children, and the subsequent psycho-social distress and physiological consequences that this poses.

Non-communicable disease mortality in young people with a history of contact with the youth justice system in Queensland, Australia: a retrospective, population-based cohort study

Young people who have had contact with the criminal justice system are at increased risk of early death, especially from injuries. However, deaths due to non-communicable diseases (NCDs) in this population remain poorly described. We aimed to estimate mortality due to NCDs in people with a history of involvement with the youth justice system, compare NCD mortality rates in this population with those in the general population, and characterise demographic and justice-related factors associated with deaths caused by NCDs in people with a history of contact with the youth justice system.

The perinatal and childhood outcomes of children born to Indigenous women with mental health problems: A scoping review

Maternal mental health problems are common during the perinatal period and have been associated with several negative outcomes in children. However, few studies have examined the associations between maternal mental health problems and offspring outcomes among Indigenous people, and the findings across these studies have been inconsistent. This scoping review examined the birth and childhood (≤12 years) health and development outcomes of the children of Indigenous women with mental health problems.

Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data

Nirsevimab is an extended half-life monoclonal antibody to the respiratory syncytial virus (RSV) fusion protein that has been developed to protect infants for an entire RSV season. Previous studies have shown that the nirsevimab binding site is highly conserved. However, investigations of the geotemporal evolution of potential escape variants in recent (ie, 2015–2021) RSV seasons have been minimal.